Best overall response of pirtobrutinib-based combination treatments
| . | PV (n = 15) . | PVR (n = 10) . | Total (N = 25) . |
|---|---|---|---|
| 15 . | 10 . | 25 . | |
| ORR, % (95% CI) | 93.3 (68.1-99.8) | 100 (69.2-100) | 96.0 (79.6-99.9) |
| Best response, n (%)∗ | |||
| CR | 7 (46.7) | 3 (30.0) | 10 (40.0) |
| PR | 7 (46.7) | 7 (70.0) | 14 (56.0) |
| SD | 1 (6.7) | 0 | 1 (4.0) |
| PD | 0 | 0 | 0 |
| Median time to best response, mo (IQR) | 3.9 (1.9- 14.7) | 1.9 (1.8- 10.7) | 2.4 (1.9-14.3) |
| . | PV (n = 15) . | PVR (n = 10) . | Total (N = 25) . |
|---|---|---|---|
| 15 . | 10 . | 25 . | |
| ORR, % (95% CI) | 93.3 (68.1-99.8) | 100 (69.2-100) | 96.0 (79.6-99.9) |
| Best response, n (%)∗ | |||
| CR | 7 (46.7) | 3 (30.0) | 10 (40.0) |
| PR | 7 (46.7) | 7 (70.0) | 14 (56.0) |
| SD | 1 (6.7) | 0 | 1 (4.0) |
| PD | 0 | 0 | 0 |
| Median time to best response, mo (IQR) | 3.9 (1.9- 14.7) | 1.9 (1.8- 10.7) | 2.4 (1.9-14.3) |
The data cutoff date was 5 May 2023.
NE, not evaluable; PD, progressive disease; SD, stable disease.
ORR is the number of patients with a best response of CR or PR divided by the total number of patients. Response status per iwCLL 2018 as assessed by the investigator.